News | July 31, 2007

New Technology May Lead to Earlier Cancer Detection

August 1, 2007 - The results of a pilot study on a new optical technology, coupled with routine endoscopy, presented in the Aug. 1 issue of Clinical Cancer Research, could represent a new approach to detecting pancreatic cancer at a very early stage.

Developed by Northwestern University biomedical engineers, the new optical technology, with routine endoscopy, exposes cellular changes indicative of cancer in tissue near the pancreas that had previously been detectable only through intensive radiologic scanning or invasive surgery.

“Pancreatic cancer is not often detected early because it is a rather inaccessible organ, so this technique holds the potential to be the first reliable, routine screening tool for pancreatic cancer,” said co-author author Randall Brand, M.D., an associate professor of medicine at Northwestern University and clinician at Evanston Northwestern Healthcare. “If we could apply this to those at high risk – such as people with chronic pancreatitis or who have a family history of pancreatic cancer– we might see a drastic improvement in pancreatic cancer survival.”

The optical technology used to detect the field effect of pancreatic cancer was developed by the senior author of the study Vadim Backman, Ph.D., a professor of biomedical engineering at Northwestern along with his graduate student, Yang Liu, Ph.D, the first author on the report. With a single instrument, Backman can use two different means of detecting the optical properties of a tissue sample, both of which were developed in his laboratory: four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS).

“We are able to use the optical properties of a cell’s structure to serve as a marker for disease,” said Backman. “These are changes within the tissue that cannot be detected through any other means. Neither antibodies nor diagnostic assays can detect them.”

According to Backman, optical markers are independent of other factors within the tissue microenvironment. “The markers do not change if the patient is a smoker. And the markers do not change with the location, stage or size of the tumor in the pancreas,” he said.

Researchers are currently involved in a larger study of the technique and its refinement. They estimate that the technology may be put into practice within three years.

The study was supported by funding from the National Science Foundation and the National Institutes of Health.

For more information: www.aacr.org

Related Content

ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...